Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome

Claire Schwab, Kathryn Roberts, Judith M. Boer, Gudrun Göhring, Doris Steinemann, Ajay Vora, Christine Macartney, Rachael Hough, Zoe Thorn, Richard Dillon, Gabriele Escherich, Giovanni Cazzaniga, Brigitte Schlegelberger, Mignon Loh, Monique L. den Boer, Anthony V. Moorman, Christine J. Harrison

Blood (2021) 137 (13): 1835–1838.

DOI: https://doi.org/10.1182/blood.2020008536

Published: 2021

Includes: Supplemental data

Journal Articles

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Blood (2020) 136 (Supplement 1): 18–19.

DOI: https://doi.org/10.1182/blood-2020-138438

Published: 2020

Journal Articles

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-134303

Published: 2020

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Clinical Trials & Observations

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

DOI: https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Clinical Trials & Observations

Blood (2020) 135 (17): 1438–1446.

DOI: https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia

Blood (2019) 134 (Supplement_1): 650.

DOI: https://doi.org/10.1182/blood-2019-125791

Published: 2019

Journal Articles

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Persis J Amrolia, FRCP, FRCPath, PhD, Robert Wynn, MD, Rachael E Hough, MD, Ajay Vora, Denise Bonney, Paul Veys, MD PhD, Robert Chiesa, Kanchan Rao, Liz Clark, Muhammad Al-Hajj, Shaun P Cordoba, PhD, Shimobi Onuoha, PhD, Ekaterini Kotsopoulou, Nushmia Z Khokhar, Martin Pule, MD, Vijay G R Peddareddigari

Blood (2019) 134 (Supplement_1): 2620.

DOI: https://doi.org/10.1182/blood-2019-123424

Published: 2019

Journal Articles

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Rachael E Hough, MD, Amy A Kirkwood, Sujith Samarasinghe, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora

Blood (2019) 134 (Supplement_1): 2579.

DOI: https://doi.org/10.1182/blood-2019-127223

Published: 2019

Journal Articles

Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia

Thomas Creasey, MBBS, Amir Enshaei, PhD, Kathryn Watts, BSc, Gavin Cuthbert, BSc, Claire Schwab, PhD, Christine J. Harrison, PhD FRCPath, Ajay Vora, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman

Blood (2019) 134 (Supplement_1): 1473.

DOI: https://doi.org/10.1182/blood-2019-122556

Published: 2019

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

DOI: https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Blood (2019) 134 (Supplement_1): 225.

DOI: https://doi.org/10.1182/blood-2019-125009

Published: 2019

Journal Articles

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Blood (2018) 132 (Supplement 1): 655.

DOI: https://doi.org/10.1182/blood-2018-99-112854

Published: 2018

Journal Articles

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Sara Ghorashian, FRCPath, PhD, Sujith Samarasinghe, Amy A Kirkwood, MSc, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Sarah Lawson, MD, Nicholas John Goulden, MD PhD MRCPath, Emma Pond, PhD, Pamela R. Kearns, PhDFRCPC, Anthony V. Moorman, PhD, John Moppett, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 656.

DOI: https://doi.org/10.1182/blood-2018-99-118426

Published: 2018

Journal Articles

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao, MD, Katherine Clesham, Jack Luke Bartram, MD, Phil Ancliff, Sara Ghorashian, FRCPath, PhD, David O'Connor, Vesna Pavasovic, Anupama Rao, MD, Sujith Samarasinghe, Carole Cairns, David Marks, David Taussig, PhD MRCP, FRCPath, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 5201.

DOI: https://doi.org/10.1182/blood-2018-99-117051

Published: 2018

Journal Articles

Acute Neurotoxicity during ALL Therapy Is Associated with Treatment Intensity, Age and Female Sex - an Analysis of SAE Reports from the UKALL 2003 Trial

Qurat-ul-Ain Wahid, Lina Hamadeh, Sheena McGowan, Rachael Hough, MD BMBS, FRCP, FRCPath, Ajay Vora, MD, Anthony V. Moorman, PhD, Christina Halsey, MD PhD

Blood (2018) 132 (Supplement 1): 1379.

DOI: https://doi.org/10.1182/blood-2018-99-113267

Published: 2018

Journal Articles

Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Persis J Amrolia, FRCP, FRCPath, PhD, Robert Wynn, MD, Rachael Hough, MD BMBS, FRCP, FRCPath, Ajay Vora, MD, Denise Bonney, Paul Veys, MD PhD, Kanchan Rao, Robert Chiesa, Muhammad Al-Hajj, Shaun P Cordoba, PhD, Shimobi Onuoha, PhD, Ekaterini Kotsopoulou, Nushmia Z Khokhar, Martin Pule, PhD, Vijay G R Peddareddigari

Blood (2018) 132 (Supplement 1): 279.

DOI: https://doi.org/10.1182/blood-2018-99-118616

Published: 2018

Journal Articles

Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies

Blood (2018) 132 (Supplement 1): 3354.

DOI: https://doi.org/10.1182/blood-2018-99-110980

Published: 2018

Journal Articles

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial

Rosanna Jackson, BSc, MSc, Philip Berry, BSc, Julie Errington, MSc, John Moppett, MD, Sujith Samarasinghe, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora, MD, Pamela R. Kearns, PhDFRCPC, Julie Irving, PhD, Gareth J Veal, PhD

Blood (2017) 130 (Supplement 1): 101.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.101.101

Published: 2017

Journal Articles

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1271.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1271.1271

Published: 2017

Journal Articles

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Maeve A O'Reilly, MB, Dinisha Govender, Ajay Vora, MD, Sujith Samarasinghe, Asim Khwaja, Victoria Grandage, Anupama Rao, Phil Ancliff, Danny Cheng, Ben Carpenter, Stephen Daw, David O'Connor, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 102.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.102.102

Published: 2017

NARROW

SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blinatumomab for infant acute lymphoblastic leukemia

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Acute Neurotoxicity during ALL Therapy Is Associated with Treatment Intensity, Age and Female Sex - an Analysis of SAE Reports from the UKALL 2003 Trial

Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only